Table 2: In vitro antiproliferative activity of selective receptor tyrosine kinase inhibitors against human DTC cells.

Tissue typeCell lineVEGFR2i1FGFRiFGFRiKITiPDGFi
SorafenibPD166866PD173074GlivecKi6783
(μM)T/N4 (μM)T/N4 (μM)T/N4 (μM)T/N4 (μM)T/N4

NormalNthy-ori 3-15.7144.6201.7

DTC2K15.20.91292.07112.39211.19.25.4
RO82-W-14.20.731.90.140.630.14211.12.51.5
FTC-1335.50.96231.649.72.11231.284.7
FTC-2367.71.3530<2.14<4.30.9330<2.14<30<2.14<
FTC-2387.31.28211.59.42.04241.321.2

Inhibitor.
2Differentiated thyroid cancer.
3IC50: the half maximal inhibitory concentration.
4T/N ratio of IC50 values of thyroid cancer cell lines to that of Nthy-ori 3-1 cells.